Hostname: page-component-7b7567c8c-lpg2g Total loading time: 0 Render date: 2026-11-15T09:45:41.638Z Has data issue: false hasContentIssue false
  • English
  • Français

Considering Wellness in Managing Patients with Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Roger S. McIntyre
Get accessRights & Permissions [Opens in a new window]

Extract

The 12-month and lifetime prevalences of bipolar I and II disorder in the United States are 2.0% and 3.3%, respectively. Similar to schizophrenia, bipolar disorder is also associated with premature and excess mortality, with an estimated loss of ∼15 years of life expectancy. Most of the excess mortality in individuals with mood disorders results from natural causes, not suicide. Again, similar to schizophrenia, the most common cause of death in patients with bipolar disorder is cardiovascular disease (CVD), which occurs approximately twice as often in this group as in the general population. Although the data are more limited than in schizophrenia, people with bipolar disorder are differentially affected by medical comorbidity. Bipolar disorder is associated with elevated risk of a wide variety of comorbid medical illnesses, including migraine, asthma, chronic bronchitis, hypertension, and gastric ulcer, which compound disability and increase the burden of the disease.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Grant, BF, Stinson, FS, Hasin, DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(10):1205–1215.CrossRefGoogle ScholarPubMed
2. Nasrallah, H, McIntyre, R, Hennekens, C, Vogel-Scibilia, S. Translating clinical data into practice: a call-to-action to raise the standard of care in the treatment of schizophrenia and bipolar disorder [transcript]. Presented at: American Psychiatric Association Media Briefing; May 23, 2006; Toronto, Canada.Google Scholar
3. Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–850.CrossRefGoogle ScholarPubMed
4. McIntyre, RS, Konarski, JZ, Soczynska, JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140–1144.CrossRefGoogle ScholarPubMed
5. McIntyre, RS, Konarski, JZ, Wilkins, K, Soczynska, JK, Kennedy, SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51(5):274–280.CrossRefGoogle ScholarPubMed
6. Taylor, V, MacQueen, G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry. 2006;67(7):1034–1041.CrossRefGoogle ScholarPubMed
7. Morriss, R, Mohammed, FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol. 2005;19(6 suppl):94–101.CrossRefGoogle ScholarPubMed
8. Wildes, JE, Marcus, MD, Fagiolini, A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. J Clin Psychiatry. 2006;67(6):904–915.CrossRefGoogle ScholarPubMed
9. Fagiolini, A, Kupfer, DJ, Houck, PR, Novick, DM, Frank, E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112–117.CrossRefGoogle ScholarPubMed
10. Hennen, J, Perlis, RH, Sachs, G, Tohen, M, Baldessarini, RJ. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004;65(12):1679–1687.CrossRefGoogle ScholarPubMed
11. Keck, PE, McElroy, SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426–1435.CrossRefGoogle ScholarPubMed
12. Tohen, M, Greil, W, Calabrese, JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162(7):1281–1290.CrossRefGoogle ScholarPubMed
13. McIntyre, RS, Konarski, JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 3):28–36.Google ScholarPubMed
14. McIntyre, RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry. 2002;63(Suppl 3):15–20.Google ScholarPubMed
15. Berk, M, Berk, L, Castle, D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 2004;6(6):504–518.CrossRefGoogle Scholar
16. Miller, K. Bipolar disorder: etiology, diagnosis, and management. J Am Acad Nurse Pract. 2006;18(8):368–373.CrossRefGoogle ScholarPubMed
17. Swann, AC. Long-term treatment in bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 1):7–12.Google ScholarPubMed